- Stocks
- Pharma & Healthcare
- Thyrocare Technologies
Thyrocare Technologies share price
NSE: THYROCAREPharma & HealthcareDiagnostics & Research
Thyrocare Technologies at a glance
Thyrocare Technologies (NSE: THYROCARE) closed at ₹470.65 on 22 Oct 2026, up 3.44% on the day. With a market capitalisation of ₹7,491 Cr, it ranks 641st by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Diagnostics & Research.
At its last close the stock traded at 46.2× trailing earnings, against a return on equity of 27.8% in FY26. Over the past year the share price has risen 11.6%. Its 52-week range is ₹342.55 (23 Mar 2026) to ₹662.00 (12 Aug 2026); the last close is 28.9% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹240 Cr (+24.3% year on year) and net profit ₹51 Cr (+33.1%), on a consolidated basis. Promoters held 60.92% of the company as of 30 Jun 2026; 100.00% of promoter shares were pledged.
Key numbers
- Market cap
- ₹7,491 CrRank 641 on NSE
- P/E (trailing)
- 46.2×
- Price to book
- 9.51×FY26
- EPS (TTM)
- ₹17.09to Q1 FY27
- ROE
- 27.8%FY26
- ROCE
- 34.6%FY26
- Debt to equity
- 0FY26
- Net profit margin
- 19.5%FY26
- Book value / share
- ₹36.78FY26
- Dividend payout
- 91.0%FY26
- 52-week high
- ₹662.0012 Aug 2026
- 52-week low
- ₹342.5523 Mar 2026
- 1-year return
- +11.6%
- RSI (14-day)
- 31.4
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | +3.44% | −4.9% | −17.7% | −15.5% | +11.6% |
Thyrocare Technologies quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹177 Cr | ₹166 Cr | ₹187 Cr | ₹193 Cr | ₹217 Cr | ₹196 Cr | ₹224 Cr | ₹240 Cr |
| Revenue YoY | +19.8% | +23.1% | +21.3% | +23.0% | +22.1% | +17.8% | +19.7% | +24.3% |
| Net profit | ₹27 Cr | ₹19 Cr | ₹22 Cr | ₹38 Cr | ₹48 Cr | ₹28 Cr | ₹48 Cr | ₹51 Cr |
| Net profit YoY | +33.8% | +30.8% | +27.6% | +56.5% | +77.9% | +45.3% | +116.8% | +33.1% |
| Net margin | 15.1% | 11.5% | 11.9% | 19.7% | 22.0% | 14.2% | 21.5% | 21.1% |
| EPS | ₹4.99 | ₹3.58 | ₹4.17 | ₹7.35 | ₹9.05 | ₹1.82 | ₹2.99 | ₹3.23 |
Thyrocare Technologies financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹6 Cr | ₹10 Cr | ₹8 Cr | ₹5 Cr | ₹6 Cr | ₹4 Cr |
| Operating profit | ₹0 Cr | ₹1 Cr | ₹0 Cr | −₹0 Cr | −₹0 Cr | ₹0 Cr |
| Net profit | ₹0 Cr | ₹1 Cr | ₹0 Cr | −₹0 Cr | −₹0 Cr | ₹0 Cr |
| EPS (₹) | ₹0.00 | ₹1.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 |
| Total debt | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹11 Cr | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | ₹427 Cr | ₹527 Cr | ₹534 Cr | ₹527 Cr | ₹547 Cr | ₹586 Cr |
Thyrocare Technologies shareholding pattern
| Holder | 30 Jun 2025 | 30 Sep 2025 | 1 Dec 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 71.06% | 71.06% | 60.93% | 60.93% | 60.92% | 60.92% |
| Foreign institutions | 3.23% | 4.85% | 5.32% | 4.95% | 5.37% | 5.44% |
| Domestic institutions | 14.54% | 13.47% | 20.17% | 20.51% | 20.99% | 20.92% |
| Non-institutions | 11.17% | 10.63% | 13.59% | 13.61% | 12.71% | 12.72% |
| Promoter shares pledged | 100.00% | 85.84% | 100.00% | 100.00% | 100.00% | 100.00% |
Thyrocare Technologies vs peers
The listed Pharma & Healthcare companies nearest to Thyrocare Technologies by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| SUVENSuven Life Sciences | ₹276.60 | −0.31% | +39.7% | ₹7,816 Cr | — | — |
| SANOFICONRSanofi Consumer Healthcare India | ₹3,325.80 | −0.28% | −29.8% | ₹7,660 Cr | 29.7 | — |
| AARTIPHARMAarti Pharmalabs | ₹838.00 | −0.91% | +1.5% | ₹7,599 Cr | 43.6 | — |
| THYROCAREThyrocare Technologies | ₹470.65 | +3.44% | +11.6% | ₹7,491 Cr | 46.2 | — |
| MOREPENLABMorepen Laboratories | ₹125.70 | +5.63% | +141.6% | ₹6,888 Cr | 72.7 | — |
| SUPRIYASupriya Lifescience | ₹848.80 | −0.02% | +19.4% | ₹6,831 Cr | 32.7 | — |
| BLISSGVSBliss GVS Pharma | ₹638.00 | +2.42% | +319.4% | ₹6,766 Cr | 53.1 | — |
Ask anything about Thyrocare Technologies
Pivot answers on the live chart with evidence you can check, and tests strategies against THYROCARE's own history. Try: “Why has THYROCARE moved over the last three months?” · “Backtest a 50-day moving-average crossover on THYROCARE over five years” · “Compare THYROCARE with SUVEN on margins and valuation”
Frequently asked questions about Thyrocare Technologies
What is the share price of Thyrocare Technologies today?
Thyrocare Technologies (NSE: THYROCARE) last closed at ₹470.65 on 22 Oct 2026. Its 52-week high is ₹662.00 and its 52-week low is ₹342.55.
What is the market cap of Thyrocare Technologies?
Thyrocare Technologies' market capitalisation is ₹7,491 Cr (₹7,491 Cr) at the 22 Oct 2026 close, ranking 641st among the NSE companies Pivot tracks.
What is the P/E ratio of Thyrocare Technologies?
Thyrocare Technologies trades at a trailing P/E of 46.2. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 43.6.
What is the ROE and ROCE of Thyrocare Technologies?
Return on equity was 27.8% in FY26 and return on capital employed was 34.6% in FY26 (consolidated figures).
Is Thyrocare Technologies a debt-free company?
Thyrocare Technologies is close to debt-free: its debt-to-equity ratio was 0 in FY26.
What were Thyrocare Technologies' latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), Thyrocare Technologies reported revenue of ₹240 Cr, +24.3% year on year, and net profit of ₹51 Cr, +33.1% year on year.
How has Thyrocare Technologies stock performed over the last year?
Thyrocare Technologies' share price has risen 11.6% over the past year, −15.5% over three months and −17.7% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Thyrocare Technologies?
As of 30 Jun 2026: promoters 60.92%, foreign institutions 5.44%, domestic institutions 20.92%, non-institutions 12.72%. 100.00% of promoter shares were pledged.
Who are Thyrocare Technologies' competitors?
The listed Pharma & Healthcare companies closest to Thyrocare Technologies by market cap are Suven Life Sciences, Sanofi Consumer Healthcare India, Aarti Pharmalabs, Morepen Laboratories, Supriya Lifescience and Bliss GVS Pharma.
Is Thyrocare Technologies a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Thyrocare Technologies' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on THYROCARE against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with T · all NSE stocks · this page as text